Oncocyte Corp Files 2024 10-K, Details Chronix Merger
Ticker: IMDX · Form: 10-K · Filed: Mar 24, 2025 · CIK: 1642380
Sentiment: neutral
Topics: 10-K, merger, securities
TL;DR
Oncocyte Corp 2024 10-K out: Chronix Merger details, April '24 stock deal. Check financials.
AI Summary
Oncocyte Corp filed its 2024 10-K on March 24, 2025, reporting its fiscal year ending December 31, 2024. The filing details the company's financial performance and business operations. Key events mentioned include the Chronix Merger and the issuance of securities through a Securities Purchase Agreement on April 15, 2024.
Why It Matters
This 10-K filing provides a comprehensive overview of Oncocyte Corp's financial health and strategic moves for the 2024 fiscal year, including significant corporate actions like the Chronix Merger.
Risk Assessment
Risk Level: medium — The filing mentions various financial instruments and corporate actions, suggesting potential complexities and risks associated with the company's operations and financial structure.
Key Numbers
- 2024 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-24 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Oncocyte Corp (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-24 (date) — Filing date
- Chronix Merger (event) — Significant corporate action
- Securities Purchase Agreement (legal_document) — Related to securities issuance
- 2024-04-15 (date) — Date of Securities Purchase Agreement
FAQ
What were the key financial outcomes for Oncocyte Corp in the fiscal year ending December 31, 2024?
The 10-K filing for the fiscal year ending December 31, 2024, provides detailed financial statements and disclosures, but specific aggregate financial outcomes like total revenue or net income are not explicitly stated in the provided snippet.
What is the significance of the Chronix Merger mentioned in the filing?
The Chronix Merger is identified as a significant corporate event for Oncocyte Corp, impacting its business operations and financial reporting as of December 31, 2023.
When was the Securities Purchase Agreement executed, and what was its purpose?
The Securities Purchase Agreement was executed on April 15, 2024, and it pertains to the issuance of securities by Oncocyte Corp.
What is Oncocyte Corp's primary business as indicated by its SIC code?
Oncocyte Corp's Standard Industrial Classification (SIC) code is 2835, which corresponds to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
What are the company's principal executive offices and contact information?
Oncocyte Corp's principal executive offices are located at 15 Cushing, Irvine, CA 92618, and the business phone number is 949-409-7600.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 24, 2025 regarding Oncocyte Corp (IMDX).